MBRX (Moleculin Biotech) Research & Development: $17.83 Mil (TTM As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $3.00
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Research & Development?

Moleculin Biotech MBRX +2.05% 30 Research & Development is $17.83 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Moleculin Biotech's Research & Development for the three months ended in Mar. 2026 was $5.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $17.83 Mil.

Moleculin Biotech  (NAS:MBRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Moleculin Biotech Research & Development Related Terms

Moleculin Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Research & Development Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.42 18.97 19.49 17.73 15.89

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 3.60 3.74 5.12 5.38
MBRX
30GF Score
Moleculin Biotech Inc MBRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $17.83 Mil mean?
Moleculin Biotech (MBRX) has a Research & Development of $17.83 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Research & Development too high?
Moleculin Biotech's current Research & Development is $17.83 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Research & Development compare to ICU and LEXX?
Moleculin Biotech's Research & Development of $17.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Research & Development is $17.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Research & Development of $17.83 Mil. The current Research & Development is $17.83 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Research & Development is $17.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price